JERUSALEM: The COVID-19 vaccine developed by Pfizer and BioNTech is effective at preventing symptomatic and severe disease in people with some chronic illnesses, like diabetes and heart disease, the biggest real-world study showed on Thursday (Apr 22).

The analysis of almost 1.2 million people by Israel’s largest healthcare provider will offer further hope for countries as they get shots into citizens’ arms, particularly those considered vulnerable, and curb the pandemic that has killed more than 3.1 million people.

The vaccine was 80 per cent effective against symptomatic infection for people with heart or chronic kidney diseases, 86 per cent for people with type 2 diabetes, 75 per cent for cerebrovascular disease, and 84 per cent for people suffering from immunodeficiency, according to the Clalit Research Institute study.

For people who were vaccinated and were already suffering three or more chronic conditions or risk factors, such as heart disease, neurological disease, chronic kidney disease, chronic lung disease, smoking, pregnancy or obesity, the research shows it was 88 per cent effective in preventing symptomatic infection.

It was more than 90 per cent effective against severe disease for people with type 2 diabetes, heart or cerebrovascular disease and 100 per cent for people suffering from immunodeficiency.

READ: How long does protection from COVID-19 vaccines last?

The data is the latest from Israel where a universal and digitised healthcare system and the speedy vaccination programme have allowed researchers insights into the vaccine’s potency. Clalit covers more than half of Israel’s population.

The results were lower than the 96 per cent overall vaccine effectiveness seven days or more after the second dose, found by the study and the 95 per cent effectiveness found in clinical trials last year.

READ  Houston's defense locks in, beats Syracuse 62-46 in NCAAs

But researchers said they offered some optimism that the vaccine still offers protection against severe illness in people who become infected after they get their shots.

“Protection is mildly reduced among patients with several co-morbidities. These results are very encouraging, as they suggest that most COVID-19 cases will be prevented by vaccination even in the elderly and chronically ill,” said Ran Balicer, Clalit’s chief innovation officer.

“People with chronic diseases, multiple chronic or severe chronic diseases, should get vaccinated because the vaccine is very effective in protecting them against the high rates of complications that are expected,” Balicer said.

The research was also carried out by Harvard and the University of Michigan and published in the New England Journal of Medicine on Thursday.

The Clalit study, compared 596,618 people vaccinated between Dec 20 2020 and Feb 14 against the same size group of unvaccinated people, matching age, gender and other characteristics.

READ: With enough supplies, Israel looks to re-route AstraZeneca COVID-19 vaccine delivery

The subgroup of the people with chronic diseases was about 130,000 people, Balicer said.

More than half of Israel’s 9.3 million population has been fully inoculated since its vaccination drive began in late December. COVID-19 cases have dropped continuously since a mid-January peak as the economy has largely opened.

Until mid-April, Israel has documented 98 per cent fewer coronavirus cases, 93 per cent fewer critically ill and 87 per cent fewer COVID-19 deaths, according to Eran Segal, data scientist at the Weizmann Institute of Science.

Balicer said that although Israel was not yet at “herd immunity”, the sharp drop was “proof of the potential of mass vaccination to really take us out of harm’s way and shows the light at the end of the tunnel”.

READ  Cambodians condemn artist who edited photos of Khmer Rouge victims

OBESITY, HYPERTENSION AND OVERWEIGHT

The large sample size allowed researchers to look more closely at subgroups of people with specific chronic diseases which would not necessarily be examined in a vaccine clinical trial, the researchers said.

It also found the vaccine to be 92 per cent effective in preventing symptomatic COVID-19 among people over the age of 70, 96 per cent for overweight people and 93 per cent for those suffering obesity and provided 90 per cent protection for people suffering from hypertension.

READ: Israel to buy millions of Pfizer COVID-19 vaccine doses

Danny Altmann, an immunology professor at the Imperial College London, said the study was among the first real world research to offer such granular data into vaccinated subgroups.

“Transitioning into real-world application, the effectiveness still looks terrific, but inevitably there are people who make poor vaccine responses,” he said in an email to Reuters.

“We need to know who they are, why, and what can be done to rescue immunity. Next, we need to see the results from each of the big cohort studies for the various patient groups.”

The US Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky said that of the 84 million people who have been fully vaccinated in the United States, fewer than 6,000 have got sick with COVID-19 more than two weeks after being fully dosed.

Of those, nearly 400 were hospitalised and around 75 died, according to CDC data. Some of the hospitalisations and deaths were not due to COVID-19 infections.

Pfizer’s late-stage clinical trial included people with co-morbidities. The most frequently reported co-morbidities were obesity (35.1 per cent), diabetes (with and without chronic complications, 8.4 per cent) and pulmonary disease (7.8 per cent), a spokesman said.

READ  DeBrincat scores in OT as Blackhawks beat Blue Jackets 3-2

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram



READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here